BioSpace News Archive

Persist AI, the AI-driven pioneer in drug formulation, announced today the close of an oversubscribed $4M financing round following their completion of YCombinator

TheracosBio today announced the publication of a study titled “ Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: a 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial ” in Diabetes, Obesity and Metabolism . The Phase 3 study assessed the safety and effectiveness of Brenzavvy™.

Adial Pharmaceuticals, Inc. announced that it will effect a 1-for-25 reverse stock split of its common stock, par value $0.001 per share, that will become effective on August 4, 2023 at 11:59 p.m. Eastern Time.

Saluda Medical, Inc. announced the publication of new health economic data in The Clinical Journal of Pain that provides the strongest ever economic case for the use of Evoke® Closed-Loop SCS with physiologic SmartLoop™ technology over open-loop SCS therapy.

Avinger, Inc. announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. into shares of a new series of convertible preferred stock.

PlasCred Circular Innovations Inc. (CSE: COVE) (OTC Pink: MGPRF) (FSE: 304) (formerly, Cover Technologies Inc.) (the “Company”) is pleased to announce that its previously announced business combination transaction (the “Transaction”) with PlasCred Inc. (“PlasCred”)

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies

The global STD diagnostics market was valued at USD 9.25 billion in 2022 and it is predicted to surpass around USD 18.59 billion by 2032 with a CAGR of 7.23% from 2023 to 2032.

Virogentics, Inc., a wholly owned subsidiary of Enzolytics, Inc., a drug development biotech company, updated the progress being made on the permit application with the European Medicine Agency for the patented immunotherapy ITV-1 treatment of HIV/AIDS virus, for use by patients after receiving chemo and radiation treatment to facilitate recovery from the treatments and those with immunodeficiency.

ImPact Biotech, the IMmune Photo Activated Cancer Treatment specialist announces the U.S. Food and Drug Administration cleared ImPact’s clinical investigation plan of Padeliporfin Vascular Targeted Photodynamic therapy for the treatment of patients with Peripheral Lung Cancer.